Status:
COMPLETED
A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors
Eligibility Criteria
Inclusion
- Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists
- Patient has good performance status (ECOG 0 or 1)
Exclusion
- Prior treatment with either gemcitabine or SU011248
- Hypertension that cannot be controlled by medications
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00615446
Start Date
March 1 2005
End Date
May 1 2009
Last Update
April 30 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
2
Pfizer Investigational Site
Boston, Massachusetts, United States, 02115
3
Pfizer Investigational Site
Boston, Massachusetts, United States, 02215